A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 101 participants.
Also called NCT03069365
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 101 participants
- Sponsor
- Registry
-
NCT03069365 -
2016-004182-60
-
- Other papers using this trial's data
- Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Germany, Greece, Italy, Poland, Puerto Rico, South Korea, Spain, Sweden
- Registry status
- Completed
Technical summary
Registry record NCT03069365. Non-randomized; no masking; primary purpose treatment. Start 2017-03-28 (actual); primary completion 2018-02-20 (actual). Results posted on 2019-03-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment
- Acronym
- EXPEDITION-5
- Condition
- Hepatitis C Virus (HCV)
- Intervention (Drug)
- Glecaprevir/pibrentasvir
- Lead sponsor
- AbbVie
Record details
- Record id
cardio:ct-nct03069365- Content hash
426d746f2685754e24e41d14e893eca4c575d9cb8dc5a37febdadbd79fbb6ceb